Jan. 11, 2017
Eli Lilly and Company has announced the expansion of an existing immuno-oncology collaboration with Merck, known as MSD outside the U.S. and Canada, to add a new study of LARTRUVO™ (olaratumab) of Lilly with Merck’s KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS).
Especially, the U.S. Food and Drug Administration (FDA) recently approved LARTRUVO (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for treating adults with STS with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with surgery or radiotherapy. European Medicines Agency has also provided conditional marketing authorization to LARTRUVO (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for treating adults with advanced STS not amenable to curative treatment with radiotherapy or surgery and who have not been previously treated with doxorubicin.
Sue Mahony, Ph.D., senior vice president and president, Lilly Oncology, said: “We look forward to further expanding our collaboration with Merck to include this combination study focused on advanced soft tissue sarcoma, a rare and difficult-to-treat disease with limited treatment options. This collaborative study builds on the exciting data we have seen with olaratumab and supports our focus on investigating the potential of rational combinations to enhance efficacy and change the standards of care for people with cancer.”
“Historic and present day scientific advances continue to reinforce the role of combination therapies in extending the lives of people with cancer. Our collaboration with Lilly exemplifies our commitment to fully exploring combination regimens with KEYTRUDA to help arm physicians with the treatment tools they need to help their patients,” said Eric Rubin, M.D., vice president and therapeutic area head, oncology early-stage development, Merck Research Laboratories.